Sep 19, 2022
AIM ImmunoTech Board Files Definitive Proxy Statement and Sends Letter to Shareholders

Sep 07, 2022
AIM ImmunoTech to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Sep 06, 2022
AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

Aug 30, 2022
AIM ImmunoTech and Study Collaborator Roswell Park Commence Enrollment in an NCI-funded Phase 2 Clinical Trial Evaluating Ampligen® (rintatolimod) in Primary PD-1/PD-L1 Resistant Melanoma

Aug 18, 2022
AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer

Aug 15, 2022
AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation

Aug 15, 2022
AIM ImmunoTech Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Jul 28, 2022
AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID

Jul 20, 2022
AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data

Jul 18, 2022
AIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are Invalid

 4   5   6   7   8     9    10   11   12   13   14